Loading…
NVCT
Nuvectis Pharma, Inc.
NASDAQ· Healthcare· Biotechnology
$23.73-5.80%
Key metrics
- Market cap
- $774.64M
- P/E
- —
- Forward P/E
- —
- P/B
- 69.8x
- Dividend yield
- —
- EPS
- -$1.24
- ROE
- -214.58%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.26
- 52-week high
- $29.28
- 52-week low
- $5.55
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
- 16
- Fort Lee, United States
Company description provided by Yahoo Finance.